CD274 and neoplasm: In the category of digestive system cancers, TIMT I subgroup (PD-L1 immunoreactivity of tumor cells and CD8 high expression of TILs) showed a significantly higher number of mutations or neoantigens in CRC and GC patients receiving anti- PD-1/PD-L1 therapy (69).